Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of Diabetic Cardiomyopathy

Hirofumi Suzuki¹,⁵, Yosuke Kayama²,⁵, Masaya Sakamoto¹,⁵, Hiroyuki Iuchi¹, Ippei Shimizu³, Takuya Yoshino², Daisuke Katoh², Tomohisa Nagoshi², Katsuyoshi Tojo¹, Tohru Minamino³,⁴, Michihiro Yoshimura², Kazunori Utsunomiya¹

¹ Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minatoku, Tokyo 105-0003, Japan
² Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan
³ Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, 2-746 Asahimachidori, Chuoku Niigata 951-8518, Japan
⁴ PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
⁵ These authors contributed equally to this work.

Address correspondence to:
Yosuke Kayama, MD, PhD
Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan
Tel: +81-3-3433-1111
Fax: +81-3-3459-6043
Email: kayama@jikei.ac.jp
Abstract
Diabetes mellitus affects cardiac structure and function, and it has been suggested that diabetes leads to cardiomyopathy. Arachidonate 12/15-lipoxygenase (12/15-LOX) has been suggested to play an important role in atherogenesis and heart failure. However, the role of 12/15-LOX in diabetic cardiomyopathy has not been examined. In this study, we investigated the effects of cardiac 12/15-LOX on diabetic cardiomyopathy. We created streptozotocin (STZ)-induced diabetic mice and compared to those of Alox15 deficient (12/15-LOX KO) mice. Expression of 12/15-LOX as well as TNF-α and NF-κB were up-regulated in STZ-induced diabetic hearts. Disruption of 12/15-LOX significantly improved STZ-induced cardiac dysfunction and fibrosis. Moreover deletion of 12/15-LOX inhibited the increases of TNF-α and NF-κB as well as the production of STZ-induced reactive oxygen species (ROS) in the heart. Administration of N-acetylcysteine (NAC) in diabetic mice prevented STZ-induced cardiac fibrosis. Neonatal cultured cardiomyocytes exposed to high glucose condition induced the expression of 12/15-LOX as well as TNF-α, NF-κB and collagen markers. These increases were inhibited by treatment of 12/15-LOX inhibitor. Our results suggest that cardiac 12/15-LOX-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy and that inhibition of 12/15-LOX could be a novel treatment for this condition.

Keywords:
Inflammation, Oxidative stress, diabetic cardiomyopathy, 12/15-lipoxygenase

Non-standard Abbreviations and Acronyms:
12/15-LOX  12/15-lipoxygenase
12/15-HETE  12/15-Hydroxyeicosatetraenoic acid
CDC        Cinnamyl-3,4-dihydroxy-α-cyanocinnamate
FS         fractional shortening
LVDs       left ventricular systolic dimension
STZ        Streptozotocin
4-HNE      4-Hydroxy-2-nonenal
ROS        Reactive oxygen species
NADPH      nicotinamide adenine dinucleotide phosphate
Nox2       nicotinamide adenine dinucleotide phosphate oxidase 2
Nox4       nicotinamide adenine dinucleotide phosphate oxidase 4
<table>
<thead>
<tr>
<th>No.</th>
<th>Protein/Peptide</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>oxidase 4</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NAC</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB</td>
<td>nuclear factor -kappa B</td>
</tr>
<tr>
<td>4</td>
<td>TNF-α</td>
<td>Tumor necrosis factor-alpha</td>
</tr>
<tr>
<td>5</td>
<td>collagen1α2</td>
<td>collagen type I alpha2</td>
</tr>
<tr>
<td>6</td>
<td>collagen3α1</td>
<td>collagen type III alpha1</td>
</tr>
<tr>
<td>7</td>
<td>Bip</td>
<td>immunoglobulin-heavy-chain-binding protein</td>
</tr>
<tr>
<td>8</td>
<td>CHOP</td>
<td>C/EBP-binding protein homologous protein</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Introduction**

Recently, the incidence of diabetes mellitus has increased rapidly, due to worldwide changes in lifestyle. The epidemic of obesity together with sedentary lifestyles are projected to result in over 300 million people having diabetes by 2025(1). According to the Framingham study, the relative rate of onset of heart failure in the diabetes is significantly high, and onset of heart failure leads to a poor prognosis for diabetes patients(2). Diabetes is an independent risk factor for heart failure. In addition, the number of cases of heart failure combined with diabetes continues to rise, and treatment will become a significant problem in the future(3). However, the detailed molecular mechanism underlying development of this pathological condition has not been elucidated yet(4; 5).

Arachidonic acid (AA) is a free fatty acid that is released from the cell membrane in response to various cytokines, peptides, and growth factors that become active under inflammatory conditions(6). There are three families of enzymes involved in the oxidative metabolism of AA. These include the LOXs, which produce leukotrienes (LT), hydroperoxyeicosatetraenoic acids (HPETEs), hydroxyeicosatetraenoic acids (HETEs), and hydroxyoctadecadienoic acids (HODEs); the cyclooxygenases (COX-1 and COX-2) which produce prostaglandins including G2 and H2 as well as thromboxanes; and cytochrome P-450 monooxygenases which produce epoxides and HETEs(7). The human LOX enzymes include 5-LOX, 12-LOX and 15-LOX(8; 9). LOX enzymes are named according to the specific carbon atoms of arachidonic acid that are oxidized. Thus, 12/15-LOX is a member of the LOX family that catalyzes the step from arachidonic acid to 12(S)-HETE and 15(S)-HETE(10). 12/15-LOX was originally isolated from porcine leukocytes(11), but its tissue distribution is now known to be relatively wide, including blood vessels, the brain, and the kidney(12).

Several lines of evidence have suggested that 12/15-LOX may play an important role in the development of atherosclerosis, nephropathy and neuropathy in diabetes mellitus(13-16). However, there is currently little evidence about a role played by 12/15-LOX in the development of diabetic cardiomyopathy. Therefore, we focused on the role of 12/15-LOX as a key molecule related to diabetic cardiomyopathy.

In the present study, we found that 12/15-LOX expression was significantly up-regulated in the heart of diabetic mice. We have shown that diabetes-induced activation of cardiac 12/15-LOX increased inflammation and oxidative stress in the diabetic heart. Conversely, disruption of 12/15-LOX reduces inflammation, oxidative stress and fibrosis in the diabetic heart, thereby improving systolic dysfunction. These findings suggest that inhibition of 12/15-LOX could be a novel treatment for diabetic
cardiomyopathy.
Research Design and Methods

Animal models. All experimental protocols were approved by Jikei University review board. Male C57BL/6 and Alox15-deficient (12/15-LOX KO) mice aged 7 weeks were used in this study. Alox15-deficient mice on a C57BL/6 background were purchased from The Jackson Laboratory. For the diabetic model, 7-week-old male C57BL/6 and Alox15-deficient mice were intraperitoneally injected with a single dose of streptozotocin (STZ) at 150mg/kg body weight (Wako 545-00283). One week after induction of diabetes, the antioxidant N-acetylcysteine (NAC) (SIGMA 9165) was administered to the three groups in the drinking water for 15 weeks (average 1.44 g/kg/day). 12/15-LOX inhibitor cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC, BIOMOL International, LP)(17), 8mg/kg once a day, was administered by subcutaneous injection for 4 weeks after induction of diabetes. We purchased the male db/db mice aged 11 weeks from CLEA Japan, Inc and used in this study.

Physiological and histological analysis. Echocardiography was performed with a Vevo 770 High Resolution Imaging System (Visual Sonics Inc.). To minimize variability of the data, heart rate was ~500-600 beats per minute when cardiac function was assessed. Average systolic pressure and heart rate were recorded by a photoelectric pulse device (Softron BP-98A, Softron Co) placed on the tail of conscious mice. 4-μm frozen cross sections of the heart were fixed in 4% paraformaldehyde and subjected to immunofluorescence staining for 12/15-LOX (Abcam ab87353), 4-Hydroxy-2-nonenal (4-HNE) (abcam ab20953) and Wheat germ agglutinin. Nuclei were stained with Hoechst (Life technologies Japan H3570). Pictures were taken on a Biorevo microscope (Keyence, BZ-9000). Cardiac tissue was fixed by perfusion with 20% Formalin Neutral Buffer Solution (Wako 136-10041), sectioned at 4-μm thickness and stained. For measurement of the percent area of cardiac fibrosis (% cardiac fibrosis), we selected 5 fields at random and calculated the ratio of Masson-stained fibrosis area to total myocardium area with the software “Photoshop CS5” (Adobe Systems Inc.) as described previously(18).

RNA analysis. Total RNA was isolated from the hearts of mice with RNA-Bee Reagent (Cosmo Bio Inc.). In brief, after preparing total RNA, first-strand cDNA was synthesized with QuantiTect® Reverse Transcription (QIAGEN Inc.). Real-time PCR was performed using Thermal Cycler Dice TP800 (TAKARA Bio Inc.) with SYBR® Premix Ex Taq™ II (TAKARA Bio Inc.) according to the manufacturer’s instructions. The specific oligonucleotide primers for GAPDH, TNF-α, collagen1α2 and collagen3α1
Western blot analysis. Whole cell lysates were prepared in RIPA buffer (Sigma-Aldrich Japan Ltd. R0278). Lysates (30 µg) were resolved by SDS-PAGE. Proteins were transferred to a PVDF membrane (Life Technologies Co. Ltd.), which was incubated with the primary antibody, followed by anti-mouse, anti-rabbit IgG, light chain specific (The Jackson Laboratory). Specific proteins were detected using enhanced chemiluminescence (ECL Prime) (GE Healthcare). The primary antibodies used for Western blotting were as follows: 4-HNE (abcam ab20953), α-Tubulin (Santa Cruz Biotechnology, Inc sc-5286) and actin (Sigma-Aldrich Japan Ltd. A4700), NF-κB p50, phosphor-NF-κB p65 (Cell Signaling Technologies #3035, #3039), Histone H3 (Cell Signaling Technologies #3638), Bip, CHOP (Cell Signaling Technologies #3183, #2895). ELISA was performed according to the manufacturer’s instructions to examine the levels of 12(S)-HETE and 15(S)-HETE (Assay Designs). We used the NE-PER® (Nuclear and Cytoplasmic Extraction kit, Thermo Fisher Scientific Inc.) for the extraction of nuclear proteins. NIH ImageJ software was used (http://rsbweb.nih.gov/ij/) to analyze intensity of Western blot bands.

Cell culture. Cardiomyocytes and cardiac fibroblasts were prepared from neonatal rats and cultured as described previously(19). Cardiomyocytes and cardiac fibroblasts were exposed to a high glucose concentration (25 mmol/L glucose; HG) and harvested at the indicated time points. Those were treated with normal glucose concentration (5.5 mmol/L glucose; LG) and 19.5mM mannitol to control for osmolarity. Cardiomyocytes were cultured in media with HG with or without 10µM CDC and 1mM N-acetyl-L-cysteine (NAC, Sigma-Aldrich Japan Ltd.) or with LG for 24-72 hours at 37°C. Palmitic acids (100uM) were treated after 48 hours after split of cardiomyocyte and incubated for 24 hours.

Measurement of intracellular ROS in cardiomyocytes. We assayed ROS production by using chloromethyl-2,7-dichlorodihydro-fluorescein diacetate (CM-H2DCFDA; Invitrogen C6827). Cardiomyocytes were cultured with 5µM CM-H2DCFDA at 37°C in the dark for 30 min and fixed the formation. CDC (10µM) was added 30min before treatment of high glucose. Pictures were taken on a Biorevo microscope (Keyence, BZ-9000). Fluorescence intensity was assessed for image analysis of the histogram by the software “Photoshop CS5”.

7
Assessment of the mitochondrial membrane potential. The mitochondrial membrane potential (ΔΨₘ) was assessed using Mito Tracker red. Briefly, cardiomyocytes were loaded with 0.5µM MitoTracker® Orange CMTMRos (Invitrogen M7510) at 37°C for 30 min, washed and fixed the formation. Fluorescence intensity was assessed by the “Photoshop CS5”.

Statistical analysis. Data are shown as the mean s.e.m. Multiple group comparisons were performed by one-way ANOVA, followed by Bonferroni’s test for comparison of means. Comparisons between two groups were made using the two-tailed unpaired Student’s t test or two-way ANOVA. In all analyses, P < 0.05 was considered statistically significant.
Results

Expression of 12/15-LOX pathway is up-regulated in the diabetic heart.

To determine whether 12/15-LOX is a key molecule in the development of diabetic cardiomyopathy, we examined the mRNA level of 12/15-LOX in the diabetic heart using RT-PCR. We created STZ-induced diabetic mice (WT-STZ) and compared them with control (saline) mice (WT). Cardiac expression of 12/15-LOX was significantly up-regulated with a peak at 4 weeks after STZ treatment in WT-STZ (Figure 1A). We next examined a production of 12(S)-HETE and 15(S)-HETE, a major metabolite of 12/15-LOX. Production of 12(S)-HETE and 15(S)-HETE were also significantly increased in the hearts of WT-STZ compared with WT through the protocol until 16 weeks after STZ treatment (Figure 1B). Immunohistochemistry showed that expression of 12/15-LOX was specifically up-regulated in cardiomyocytes of diabetic heart, but not in vascular cell and fibroblast cell (Figure 1C).

Animal characteristics of Wild and Alox15-deficient mice after STZ treatment

To investigate the relationship between up-regulation of 12/15-LOX and STZ-induced diabetic cardiomyopathy, we created STZ-induced diabetic mice using Alox15-deficient mice (KO) and compared them to WT-STZ mice. Animals were divided into 4 groups (WT, KO, WT-STZ, KO-STZ). Blood pressure (systolic blood pressure; SBP, diastolic blood pressure; DPB), heart rate, plasma glucose levels and body weight, in each animal were measured at 0, 8 and 16 weeks after saline (WT, KO) or STZ (WT-STZ, KO-STZ) treatment. Single injection of STZ (150 mg/kg ip) to adult male mice resulted in strongly high plasma glucose levels for a week after STZ treatment. Same dose of saline was injected as a control. High dose STZ-induced model has been established as a diabetes model and recognized as a useful model of diabetic cardiomyopathy(13; 20). There was no difference in blood pressure and heart rate among the 4 groups under normal or STZ-induced high glucose conditions. Plasma glucose levels remained around 10mmol/L in WT and KO mice without STZ treatment. No difference in plasma glucose level was observed between WT and KO, WT-STZ and KO-STZ at every weeks of age. Although body weight was not a tendency to increase at advancing age in mice after STZ treatment than control mice, there was no difference between WT and KO, WT-STZ and KO-STZ (Table).

Disruption of 12/15-LOX improves cardiac dysfunction and fibrosis induced by hyperglycemia.

Echocardiography was performed at 0, 8, 16 weeks after saline or STZ treatment and
compared between 4 groups. Fractional shortening (FS) was gradually impaired and left ventricular systolic dimension (LVDs) was increased in WT-STZ from 8 weeks after induction of diabetes compared with those of WT. In contrast, systolic dysfunction and left ventricular dilatation were not observed in KO and KO-STZ (Figure 2A). Histological examination revealed that 16 weeks after induction of diabetes, the fibrotic area progressively extended to the peri-vascular and interstitial areas in WT-STZ heart compared to WT heart. This increase was significantly inhibited in KO-STZ heart compared to that of WT-STZ (Figure 2B). Quantitative analysis revealed that % cardiac fibrosis was significantly decreased in KO-STZ compared to those of WT-STZ (Figure 2C). These results suggest that 12/15-LOX affects cardiac dysfunction of STZ-induced diabetic cardiomyopathy and the increased expression of 12/15-LOX-induced by hyperglycemia might cause cardiac dysfunction and fibrosis.

**Disruption of 12/15-LOX decreases cardiac inflammation and oxidative stress induced by hyperglycemia.**

We next examined the expression of inflammatory cytokine genes by RT-PCR. We found that cardiac expression of tumor necrosis factor-α (TNF-α) was up-regulated in WT-STZ heart compared to WT heart (Figure 3A). Cardiac collagen markers such as collagen1α2 and collagen3α1 were also increased in WT-STZ heart compared to WT heart at every four-week after STZ treatment, these increase were canceled by disruption of 12/15-LOX (Figure 3B). Moreover, we examined the relationship between 12/15-LOX expression and activation of NF-κB in WT-STZ heart and KO-STZ heart by western blot analysis. Cardiac activation of NF-κB was up-regulated in WT-STZ heart compared to WT heart. This up-regulation of NF-κB was also inhibited by disruption of 12/15-LOX (Figure 3C, 3D), indicating that 12/15-LOX may induce cardiac inflammation, which was involved in the development of STZ-induced diabetic cardiomyopathy.

**12/15-LOX induces cardiac oxidative stress in the diabetic heart.**

We examined the relationship between 12/15-LOX and cardiac oxidative stress in the diabetic heart. Immunohistological staining and western blotting showed that expression of cardiac 4-HNE, a major marker of oxidative stress, was up-regulated in myocardium in WT-STZ heart compared to WT heart, and this enhancement was significantly inhibited by disruption of 12/15-LOX (Figure 4A, 4B, 4C). We next examined the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase isoforms by RT-PCR at 4 weeks after induction of diabetes. Among the NADPH isoforms, expression of
nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) but not nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) was up-regulated in WT-STZ heart compared to WT heart and KO heart. This increase was also inhibited in KO-STZ heart (Figure 4D).

To investigate the subcellular mechanism of the increase in reactive oxygen species (ROS) in the diabetic heart, intracellular ROS levels in cardiomyocytes were estimated under HG and LG by fluorimetry in vitro. Cardiomyocytes under HG showed enhancement of fluorescence intensity of DCF-DA by 7 fold at 24 hours compared to findings for those under LG (Figure 4E, 4F). Treatment with 12/15-LOX inhibitor (CDC) inhibited the enhancement of DCF-DA fluorescence under HG condition (Figure 4E, 4F). To further investigate the subcellular origins of ROS production in the diabetic heart, we used MitoTracker® Red to evaluate the effect of HG on the mitochondrial membrane potential in cardiomyocytes. The result showed that there was loss of mitochondrial membrane potential ($\Delta \Psi_m$) as indicated by a decrease in the fluorescence intensity of MitoTracker® Red in cardiomyocytes under HG. This decrease in the fluorescence intensity was improved by treatment with CDC (Figure 4E, 4F).

These in vivo and in vitro results suggest that activation of NADPH oxidase and mitochondrial membrane abnormalities were occur in the diabetic heart and 12/15-LOX pathway is involved in the process of production of ROS and oxidative stress in the diabetic heart.

Cardiac fibrosis and inflammation are ameliorated by treatment with antioxidant in the diabetic heart

To investigate the relationship between cardiac oxidative stress and cardiac inflammation, we examined the hearts of WT-STZ mice who were administered the antioxidant N-acetylcysteine (NAC) in their drinking water (WT-STZ NAC) throughout the experimental period and compared them to the heart of WT, KO, WT-STZ and KO-STZ mice. NAC was administered to diabetic mice for 15 weeks and histological analysis and cardiac expressions of TNF-α, collagen1α2, and collagen3α1 were examined. Histological examination revealed that cardiac peri-vascular fibrosis was improved in WT-STZ NAC heart as well as KO-STZ heart compare to findings in the WT-STZ heart (Figure 5A). Quantitative analysis revealed that the percentage of cardiac fibrosis was significantly decreased in KO-STZ and WT-STZ NAC hearts compared to those of WT-STZ hearts (Figure 5B). Moreover, RT-PCR showed that increased expression of TNF-α, collagen1α2 and collagen3α1 in WT-STZ NAC and KO-STZ hearts were significantly inhibited compare with the expressions in WT-STZ.
hearts (Figure 5C, 5D). These results indicate that cardiac oxidative stress has a major role in promoting cardiac inflammation in the STZ-induced diabetic heart.

**Cardiac 12/15-LOX pathway induced by high glucose condition increases the expression of cardiac inflammation in vitro.**

To further investigate the role of 12/15-LOX in cardiomyocytes under HG, we cultured neonatal cardiomyocytes under LG and HG using mannitol to adjust osmotic pressure for 24, 48 and 72 hours. RT-PCR showed that hyperglycemia up-regulated the expression of 12/15-LOX in cardiomyocytes (Figure 6A). Production of 12(s)-HETE and 15(s)-HETE were also increased in cardiomyocytes under HG condition (Figure 6B).

Furthermore, RT-PCR demonstrated the up-regulation of TNF-α, collagen1α2 and collagen3α1 in cardiomyocytes under HG after 24 hours (Figure 6C, 6D). To determine whether increased expression of cardiac 12/15-LOX affects the up-regulation of TNF-α, collagen1α2 and collagen3α1 in cardiomyocyte, we cultured neonatal cardiomyocytes with CDC under HG and examined the expression of each markers. Increased expression of TNF-α, collagen1α2 and collagen3α1 under HG were inhibited by treatment with CDC (Figure 6C, 6D). These results suggest that, cardiac 12/15-LOX induced by hyperglycemia implicated the up-regulation of inflammatory cytokines such as TNF-α, collagen1α2 and collagen3α1.

**Treatment of antioxidant inhibits cardiac inflammation induced by high glucose condition in vitro**

We next investigated the relationship between the oxidative stress and inflammation induced by hyperglycemia in cardiomyocytes. Treatment with NAC under HG, RT-PCR showed that up-regulation of TNF-α, collagen1α2 and collagen3α1 in cardiomyocytes was inhibited (Figure 7A, 7B). Moreover, western blotting revealed that nucleus cardiac activation of NF-κB using anti-NF-κB p50 antibody and anti phospho-NF-κB p65 (Ser468) antibody was up-regulated under HG compared to under LG after 24 hours. This activation of NF-κB was significantly inhibited by treatment with NAC in cultured cardiomyocytes (Figure 7C, 7D).
Discussion

In the present study we demonstrate that the arachidonate 12/15-LOX is an important molecule involved not only in the onset and development of diabetic cardiomyopathy, but also in increased inflammation and oxidative stress in the heart.

It has been known for a long time that after STZ administration, alternations occur in the enzymatic activity of cardiac contractile proteins, such as myosin and actomyosin, in rats and mice, and that cardiac contractile function gradually deteriorates (4; 21). This finding has provided a basis for the well-known diabetic cardiomyopathy model, where STZ administration quickly increases plasma glucose levels, and high plasma glucose levels are maintained for a long time, as shown in our experiments as well. In the hearts of wild-type mice exposed to increased plasma glucose levels, cardiac 12/15-LOX expression peaked at 4 weeks and its up-regulation persisted until 16 weeks after administration. Immunohistochemistry showed that the expression of 12/15-LOX in the heart was specifically up-regulated in cardiomyocytes but not in vascular and fibroblast cells. Cardiac function gradually deteriorated from 8 weeks onward after STZ administration, whereas this deterioration was suppressed in the Alox15-deficient mice. These results suggest that 12/15-LOX is involved in the onset and development of STZ-induced diabetic cardiomyopathy.

Arachidonic acid (AA) metabolites are known to be involved in the development of tissue inflammation and fibrosis in non-cardiovascular diseases such as pulmonary fibrosis (22; 23), suggesting an important role for AA as a potential pathway in the pathogenesis of cardiac fibrosis. A number of papers have demonstrated that the 12/15-LOX pathway induces inflammation in a variety of tissues. For example, overexpressed 12/15-LOX in macrophage-like J774.1 cells and HVSMC increased production of inflammatory cytokines such as interleukin-6 and TNF-α (24; 25). In an experimental asthma model, 12/15-LOX inhibition reduced airway inflammation and attenuated cell injury (26). Furthermore, 12/15-LOX caused cell growth of cardiac fibroblasts and matrix production in the heart (27) and mice with cardiac overexpression of 12/15-LOX showed increased the expressions of MCP-1 and TNF-α thereby inducing cardiac fibrosis and dysfunction (28). TNF-α is an important molecule that triggers inflammation and cell injury in the heart (29), which is known to induce cardiac fibrosis as
a consequence (30; 31). Its suppression has been shown to improve diabetic
cardiomyopathy, reduce cardiac fibrosis, and recover cardiac function (21; 32;
33). In agreement with these findings, our results showed that the
expressions of TNF-α and collagen markers were elevated accompanied by
an increase in the expression of 12/15-LOX in the STZ-induced diabetic heart,
whereas these increases were suppressed in the Alox15-deficient mice
leading to cardiac function being preserved. Moreover, administration of a
12/15-LOX inhibitor (CDC) suppressed the up-regulation of TNF-α
associated with high blood glucose levels in vitro. Our findings suggest that
12/15-LOX-induced TNF-α may have a major role in the development of
cardiac fibrosis in STZ-induced diabetic cardiomyopathy.

Oxidative stress has been well-known to be involved in the
development of diabetic cardiomyopathy, and increased ROS production is
shown to induce various cardiovascular complications including cardiac
dysfunction(32). Accumulating evidence suggests that mitochondria and
NADPH oxidase are an important source of ROS production in the diabetic
heart(34-36) where the crosstalk between mitochondria and NADPH oxidase
are an important represents a feed-forward vicious cycle of ROS
production(37; 38). It is important to elucidate the cellular mechanisms of
ROS increase in the diabetic heart. Our histological examination revealed
that cardiac production of 4-HNE was increased in the diabetic heart and
DCF fluorescence showed that intracellular ROS levels in cardiomyocytes
were increased under high glucose conditions. We also showed the cardiac
expression of NOX4, one of the NADPH homologues, is elevated in the
diabetic heart and the mitochondrial membrane potential is decreased in
cardiomyocytes exposed to high glucose levels in vitro. Moreover, disruption
of 12/15-LOX decreased the production of 4-HNE and expression of NOX4 in
the diabetic heart, while 12/15-LOX inhibitor (CDC) decreased intracellular
ROS levels in cardiomyocytes and restored the mitochondrial membrane
potential. These results suggest that oxidative stress is increased in the
diabetic heart and production of ROS in cardiomyocyte generated from
mitochondria and NADPH oxidase plays a pivotal role in the onset and
development of diabetic cardiomyopathy. Moreover, our results suggest that
12/15-LOX is an important molecule involved in the process of production of
ROS and oxidative stress in the diabetic heart.

Recently, diabetic patients with hypertension have increased in
numbers with the risk of cardiovascular disease thought to be increased in these patients. Research into molecules involved in both diseases is of critical importance, given that any such molecule will likely represent a viable therapeutic target in the future. Diabetes not only causes hyperglycemia and increases oxidative stress, but also exhibits a complicated disease condition associated with concomitant hypertension eventually leading to atherosclerosis and organ injury(39). Persistent hyperglycemia associated with diabetes, insulin resistance, and postprandial hyperglycemia induces inflammation and oxidative stress and causes myocardial injury(40; 41). We previously confirmed by microarray analysis that 12/15-TLOX was up-regulated in the heart of a hypertensive heart failure model and demonstrated that it is involved in the inflammation of the heart and development of cardiac fibrosis(28). Our present in vivo and in vitro studies demonstrate that 12/15-LOX is involved in the development of disease not only in the hypertensive heart failure model but also in the STZ-induced diabetic cardiomyopathy model, suggesting that 12/15-LOX is an important molecule affecting the heart in both diseases.

It has been shown that 12/15-LOX is involved in the onset of a variety of diseases associated with type 1 and type 2 diabetes, such as cardiovascular disease, hypertension, renal disease, and neurodegenerative disorders. Furthermore, the role of 12/15-LOX has been suggested in humans as well. Indeed, the expression of 12/15-LOX was shown to be an independent risk factor for atherosclerosis in 828 patients with diabetes(42), and 12/15-LOX inhibition is shown to lead to reductions in the size of cerebral infarction in humans(43-46).

We acknowledge several limitations of our study. First, not all groups were evaluated over the entire course of cardiac fibrosis development in the study. Second, we could not entirely exclude the effects of the pharmacological agents used, such as CDC and NAC, especially on cardiac fibrosis, due to lack of several control groups in the study. Furthermore, while we demonstrated that the active involvement of ROS in high glucose leads to the up-regulation of 12/15-LOX, which, in turn, results in cardiac fibrosis, the precise mechanisms linking 12/15-LOX to profibrotic signaling still remain largely unknown. Despite these limitations, however, we believe we have provided important new insights into diabetic cardiomyopathy.

In conclusion, this study demonstrated the mechanisms through
which the expression of 12/15-LOX in the heart, associated with persistent
hyperglycemia, leads to the development of diabetic cardiomyopathy via
cardiac inflammation and oxidative stress. Moreover, it was suggested that
inhibition of 12/15-LOX could potentially be a useful treatment for not only
diabetic cardiomyopathy but also for diabetic complications.

Acknowledgments
No other potential conflicts of interest relevant to this article were reported. H.S.
conducted experiments, performed data analyses and wrote the manuscript. Y.K. and
M.S. designed research, analyzed data, and wrote the manuscript. I.S., H.I., T.Y. and
K.T. contributed to experimental work (Staining analysis and animal care). T.N., K.T.
and M.Y. contributed to discussion. T.M. designed research, analyzed data and
contributed to reviewed/edited the manuscript. K.U. is the guarantor of this work and, as
such, had full access to all the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis. We thank Y. Inada and Y. Takada for
research assistance and technical support (Division of Diabetes, Metabolism and
Endocrinology, Department of Internal Medicine, Jikei University School of Medicine).

Sources of Funding
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of
Education, Culture, Sports, Science and Technology of Japan, and from Uehara
Memorial Foundation (to YK).

Author Information
The authors declare no competing financial interests.

Disclosures
None
Wild type mice (WT) and *Alox15-deficient mice* (KO) were used to create a streptozotocin (STZ)–induced diabetic mice. Animals were divided into 4 groups (WT, KO, WT-STZ, KO-STZ). Blood pressure (Systolic blood pressure; SBP, Diastolic blood pressure; DBP), heart rate, plasma glucose levels and body weight, in each animal were measured at 0, 8 and 16 weeks after saline (WT, KO) or STZ (WT-STZ, KO-STZ) treatment (Table 2). *P<0.05 vs. WT (0w), **P<0.01 vs. WT (0w), #P<0.05 vs. KO (0w), ##P<0.01 vs. KO (0w), †P<0.05 vs. WT (16w), ¶P<0.05 vs. KO (16w). Results represent mean s.e.m. n=10-15.

Table  Animal characteristics of Wild and *Alox15*-deficient mice after STZ treatment

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Wild (WT)</th>
<th><em>Alox15</em>-deficient (KO)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0w</td>
<td>8w</td>
</tr>
<tr>
<td>Blood pressure (mmHg) (SBP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>105.7(3.4)</td>
<td>100.2(2.1)</td>
</tr>
<tr>
<td>WT-STZ</td>
<td>108.1(5.0)</td>
<td>108.6(4.9)</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>627(19)</td>
<td>655(9)</td>
</tr>
<tr>
<td>WT-STZ</td>
<td>615(25)</td>
<td>583(35)</td>
</tr>
<tr>
<td>Plasma glucose (mol/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>10.1(0.4)</td>
<td>11.9(1.0)</td>
</tr>
<tr>
<td>WT-STZ</td>
<td>10.3(0.6)</td>
<td>31.2(0.5)**</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>22.6(0.4)</td>
<td>26.8(1.0)*</td>
</tr>
<tr>
<td>WT-STZ</td>
<td>22.4(1.0)</td>
<td>20.9(0.5)* †</td>
</tr>
</tbody>
</table>
**Figure Legends**

**Figure 1** *Expression of 12/15-LOX pathway is up-regulated in the diabetic heart.*

(A) Expression of 12/15-LOX in the hearts of wild-type (WT), wild-STZ (WT-STZ) mice by RT-PCR. Cardiac expression of 12/15-LOX was up-regulated in WT-STZ compared to WT at every weeks of age. (B) 12/15(S)-HETE levels in the hearts of WT and WT-STZ by ELISA. Production of 12/15(S)-HETE was increased in the hearts of WT-STZ compared to WT. *P<0.05 **P<0.01 WT-STZ vs. WT. Error bars indicate s.e.m. n= 10-15 in each group. (C) Immunofluorescence staining of 12/15-LOX in the hearts of WT and WT-STZ at 4 weeks after induction of diabetes. Expression of 12/15-LOX (red) was specifically up-regulated in cardiomyocytes of diabetic hearts. Wheat germ agglutinin (WGA) was used to label cardiomyocytes membranes (green). Upper panel is the staining of cardiomyocytes membranes (green). Middle panel is the staining of 12/15-LOX (red). Lower panel is the merged image of 12/15-LOX, cardiomyocytes membranes and hoechst staining. Scale bar, 60µm.

**Figure 2** *Disruption of 12/15-LOX improves cardiac dysfunction and fibrosis induced by hyperglycemia.*

(A) Echocardiographic findings in wild-type (WT), wild-STZ (WT-STZ), *Alox15-deficient* (KO) and *Alox15-deficient-STZ* (KO-STZ) mice. Left ventricular FS was gradually decreased and the LVDd was increased in WT-STZ compared with WT. These changes observed in WT-STZ were further exacerbated by aging. FS and LVDs were improved in KO-STZ compared to WT-STZ. *P<0.05 vs. WT, #P<0.05 vs. KO-STZ (16w). Error bars indicate s.e.m. n= 10-15 in each group.

(B) Masson Trichrome staining in the hearts of WT, WT-STZ, KO-STZ at 16 weeks after induction of diabetes. An increase in peri-vascular and interstitial fibrosis was observed in WT-STZ; this fibrosis decreased in KO-STZ mice. Scale bar, 60µm. The percentage area of fibrosis in the hearts of WT, WT-STZ and KO-STZ. *P<0.05 vs. WT, #P<0.05 vs WT-STZ. Error bars indicate s.e.m. n=7-10.

**Figure 3** *Disruption of 12/15-LOX decreases cardiac inflammation and oxidative stress induced by hyperglycemia.*

(A, B) RT-PCR analysis for tumor necrosis factor-α (TNF-α), collagen markers collagen1α2 and collagen3α1 in the hearts of wild-type (WT), wild-STZ (WT-STZ) and *Alox15-deficient-STZ* (KO-STZ) mice at 4-16 weeks after induction of diabetes. Cardiac expression of TNF-α, collagen1α2 and collagen3α1 was up-regulated in
WT-STZ compared to WT hearts. These increases were also inhibited by disruption of 12/15-LOX. *P<0.05  **P<0.01 vs. WT,  #P<0.05  ##P<0.01 vs. WT-STZ. Error bars indicate s.e.m. n=7-10. (C) Western blot analysis of NF-κB activation in the hearts of WT, WT-STZ and KO-STZ using anti-histone antibody and anti-NF-κB p50 antibody. We extracted the nuclear proteins of NF-κB p50 by using Nuclear and Cytoplasmic Extraction kit. (D) Analyzing intensity of Western blot bands showed that cardiac activation of NF-κB was up-regulated in WT-STZ heart compared to WT heart. The increased expression of NF-κB was also inhibited by disruption of 12/15-LOX. *P<0.05 vs. WT,  #P<0.05 vs. WT-STZ. Data are shown as mean+s.e.m of duplicates and are representative of 1 experiment out of 5.

**Figure 4  12/15-LOX induces the cardiac oxidative stress in the diabetic heart.**

(A) Immunohistological staining (brown) of 4-Hydroxy-2-nonenal (4-HNE) in the hearts of wild-type (WT), Alox15-deficient (KO), wild-STZ (WT-STZ) and Alox15-deficient-STZ (KO-STZ) mice. Upper panel is x20, lower panel is x400, Scale bar, 1mm and 30µm. (B) Western blot analysis of 4-HNE expression in the hearts of WT, KO, WT-STZ and KO-STZ using anti-4-HNE antibody and anti-actin antibody. (C) Analyzing intensity of Western blot bands showed that cardiac 4-HNE level (38kD) was significantly increased in WT-STZ compared to WT hearts and this increase was significantly inhibited by disruption of 12/15-LOX. *P<0.05 vs. WT,  #P<0.05 vs. KO-STZ. Data are shown as mean+s.e.m of duplicates and are representative of 1 experiment out of 5. (D) RT-PCR analysis for NADPH oxidase 2 (Nox2) and 4 (Nox4) in the hearts of WT, KO, WT-STZ and KO-STZ was examined at 4 weeks after induction of diabetes. *P<0.05 vs. WT,  #P<0.05 vs. WT-STZ. Error bars indicate s.e.m. n=4-6. (E) Representative images of CM-H2DCFDA and MitoTracker® Orange CMTMRos fluorescence in cultured neonatal cardiomyocytes under normal glucose (LG), high glucose (HG) and high glucose+12/15-LOX inhibitor (CDC 10µmol/L) (HG+CDC) groups. (F) Quantitative results of analysis. Treatment of CDC significantly attenuated the increase of ROS caused by high glucose condition. *P<0.05 vs. LG,  #P<0.05 vs. HG. Error bars indicate s.e.m. n=4-6.

**Figure 5  Cardiac fibrosis and inflammation are ameliorated by treatment with antioxidant in the diabetic heart.**

(A) Masson Trichrome staining in the hearts of wild-type (WT), Alox15-deficient (KO), wild-STZ (WT-STZ), Alox15-deficient-STZ (KO-STZ) and wild-STZ with NAC (WT-STZ+NAC) at 16 weeks after induction of diabetes. An increase in peri-vascular
and interstitial fibrosis was observed in WT-STZ; this fibrosis decreased in WT-STZ+NAC. Scale bar, 60µm. (B) The percentage area of fibrosis in the hearts of WT, KO, WT-STZ and WT-STZ+NAC. *P<0.05 vs. WT, #P<0.05 vs WT-STZ+NAC. Error bars indicate s.e.m. n=7-10. (C, D) RT-PCR analysis for TNF-α, collagen1α2 and collagen3α1 in the hearts of WT, KO, WT-STZ and WT-STZ+NAC at 4-16 weeks after induction of diabetes. Cardiac expression of TNF-α, collagen1α2 and collagen3α1 were up-regulated in WT-STZ compared with WT hearts. These increases were also inhibited by NAC. *P<0.05 **P<0.01 vs. WT, #P<0.05 ##P<0.01 vs. WT-STZ+NAC. Error bars indicate s.e.m. n=5-10.

**Figure 6** Cardiac 12/15-LOX pathway induced by hyperglycemia increases the expression of cardiac inflammation in vitro.
Cardiomyocytes were treated with high glucose condition (25 mmol/L; HG) or normal glucose condition (5.5 mmol/L; LG) for the indicated times (0-72h). (A) Expression of 12/15-LOX in cardiomyocytes by RT-PCR. (B) Production of 12/15(s)-HETE in cardiomyocytes by ELISA. *P<0.05 vs. LG, #P<0.05 vs. HG. Error bars indicate s.e.m. n=4-7.
Cardiomyocytes were treated with 12/15-LOX inhibitor (CDC 10µmol/L) for the indicated time (24-72 hours). (C, D) Expression of TNF-α, collagen1α2 and collagen3α1 in cardiomyocytes treated with LG, HG and HG with CDC by RT-PCR. Up-regulation of TNF-α, collagen1α2 and collagen3α1 under HG were inhibited by treatment with CDC. *P<0.05 vs. LG, #P<0.05 vs. HG. Error bars indicate s.e.m. n=4-7.

**Figure 7** Treatment of antioxidant inhibit cardiac inflammation induced by high glucose condition in vitro.
Cardiomyocytes were treated with high glucose condition (25 mmol/L; HG) or normal glucose condition (5.5 mmol/L; LG) for the indicated times (0-72h) (A, B) Expression of TNF-α, collagen1α2 and collagen3α1 in cardiomyocyte by RT-PCR. Up-regulation of TNF-α, collagen1α2 and collagen3α1 in cardiomyocytes under HG were inhibited by treatment with NAC. *P<0.05 vs. LG, #P<0.05 vs. HG. Error bars indicate s.e.m. n=4-7. (C) Western blot analysis of NF-κB activation in cardiomyocytes using anti-NF-κB p50 antibody, anti-phospho-NF-κB p65 (Ser468) antibody and anti-histone antibody. (D) Analyzing intensity of Western blotting showed that cardiac activation of NF-κB was up-regulated in HG compared to LG after 24 hours. The activation of NF-κB was also inhibited by treatment with NAC. *P<0.05 vs. LG, #P<0.05 vs. HG. Data are shown as mean+s.e.m of duplicates and are representative of 1 experiment out of 5.
References

35. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, Yun UJ, McQueen AP,
Wayment B, Litwin SE, Abel ED: Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008;57:2924-2932


38. Lee SB, Bae IH, Bae YS, Um HD: Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. The Journal of biological chemistry 2006;281:36228-36235


Fig1A

Relative expression of 12/15-LOX

WT

WT-STZ

Fig1B

12(S)-HETE (pg/µg protein)

WT

WT-STZ

15(S)-HETE (pg/µg protein)

WT

WT-STZ

n=10-15, *: P<0.05, **: P<0.01
Figure 1C

WT

WT-STZ

WGA

12/15-LOX

Merge

Bar. 60μm
Figure 2A

n=10-15, *: P<0.05, #: P<0.05

Diabetes
Figure 2B

16 weeks

WT
KO
WT-STZ
KO-STZ

Masson stain  Bar.60μm  x200

Figure 2C

n=7-10, *: P<0.05, #: P<0.05
Figure 3A

Figure 3B

n=7-10, *P<0.05, **P<0.01, #P<0.05, ##P<0.01
**Figure 3C**

**NF-κB p50**

**Histone**

---

**Figure 3D**

<table>
<thead>
<tr>
<th></th>
<th>NF-κB p50/ Histone Relative expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td><img src="image" alt="Bar chart" /></td>
</tr>
<tr>
<td>WT-STZ</td>
<td><img src="image" alt="Bar chart" /></td>
</tr>
<tr>
<td>KO-STZ</td>
<td><img src="image" alt="Bar chart" /></td>
</tr>
</tbody>
</table>

- n=5, *P<0.05, #P<0.05
Figure 4A
Figure 4B

WT  KO  WT-STZ  KO-STZ

4-HNE

Actin

Figure 4C

N=4, *P<0.05, #P<0.05
Figure 4D

Relative expression of Nox2 and Nox4 in WT, KO, WT-STZ, and KO-STZ groups. n=4-6, *P<0.05, #P<0.05.
Figure 4E

CM-H2DCFDA

Mito tracker

Figure 4F

n=4-6, *P<0.05, #P<0.05
**Figure 5A**

16 weeks

WT | KO | WT-STZ | KO-STZ | WT-STZ+NAC

Masson stain Bar.60μm x200

**Figure 5B**

[Graph showing %Fibrosis]
Figure 5C

Figure 5D

n=5-10, *P<0.05, **P<0.01, ***P<0.001
Figure 6A

24hr

48hr

72hr

12/15-LOX Relative expression

LG

HG

n=4-7, *P<0.05
Figure 6B

![Bar charts showing the levels of 12(S)-HETE and 15(S)-HETE over 72 hours for different groups: LG, HG, and HG+CDC.](image)

- **12(S)-HETE (pg/μg protein)**
  - 24hr, 48hr, and 72hr values are plotted for each group.
  - Significant differences are indicated by asterisks (*) and hash marks (#).

- **15(S)-HETE (pg/μg protein)**
  - Similar data points are shown as above for 24hr, 48hr, and 72hr.

**Legend:**
- LG (light gray)
- HG (black)
- HG+CDC (dark gray)

**Statistical Significance:**
- *P<0.05
- n=4-7

*Diabetes*
Figure 6C

Figure 6D

n=4-7, *P<0.05, #P<0.05
Figure 7A

![Graph showing TNF-α relative expression with bars for LG, HG, and HG+NAC conditions. *P<0.05, #P<0.05.]

Figure 7B

![Graphs showing Collagen1α2 and Collagen3α1 relative expression with bars for LG, HG, and HG+NAC conditions. *P<0.05, #P<0.05.]

n=4-7, *P<0.05, #P<0.05
Figure 7C

NF-κB p50

Phospho NF-κB p65

Histone

Figure 7D

n=5, *P<0.05, #P<0.05
Supplementary figure1
Supplementary figure 2

Cardiac fibroblasts
12/15-LOX
Relative expression

Cardiac fibroblasts
15(S)-HETE (pg/μg protein)

Cardiac fibroblasts
12(S)-HETE (pg/μg protein)

n=4-7
Supplementary figure 4

n=4-6, *P<0.05
Supplementary figure 5

PLA: Palmitic acid (100uM)

n=4 each
Supplementary figure 6

The bar graph shows the relative expression of 12/15-LOX in different groups: WT, WT-STZ, and WT-STZ+Insulin. The expression is measured on a log scale.

- WT: Low expression
- WT-STZ: High expression
- WT-STZ+Insulin: Expression similar to WT

Statistical significance:
- *P<0.05
- #P<0.05

N=4-6
Supplementary figure 7

- **Bip**
  - WT
  - WT-STZ
  - KO-STZ

- **CHOP**
  - WT
  - WT-STZ
  - KO-STZ

- **α-Tubulin**
  - WT
  - WT-STZ
  - KO-STZ
Supplemental figure legends

Figure S1  **12/15(S)-HETE levels in the heart between WT, KO, WT-STZ, KO-STZ mice.**
Production of 12/15(S)-HETE levels in the hearts of wild-type (WT), wild-STZ (WT-STZ), Alox15-deficient (KO), Alox15-deficient-STZ (KO-STZ) mice by ELISA. There were no differences of 12/15(S)-HETE between WT, KO and KO-STZ. *P<0.05 **P<0.01 vs. WT, #P<0.05 ##P<0.01 vs. WT-STZ. Error bars indicate s.e.m. n= 10-15 in each group.

Figure S2  **Expression of 12/15-LOX pathway is not up-regulated in Cardiac fibroblasts induced by high glucose condition in vitro**
Cardiac fibroblasts were treated with a high glucose concentration (25 mmol/L glucose; HG) or with 5.5 mM glucose and 19.5 mM mannitol (Low glucose; LG) to control for osmolarity for the indicated times (24-72h). (A) Expression of 12/15-LOX in cardiac fibroblasts by RT-PCR. (B) Production of 12/15(s)-HETE in cardiac fibroblasts by ELISA. Error bars indicate s.e.m. n=4-7.

Figure S3  **Expression of 12/15-LOX pathway is up-regulated in hearts of obese diabetic db/db mice.**
(A) Expression of 12/15-LOX in hearts of obese diabetic db/db mice at 11 weeks of age by RT-PCR. (B) Production of 12/15(s)-HETE in hearts of obese diabetic db/db mice at 11 weeks of age by ELISA. (C) Immunofluorescence staining of 12/15-LOX in the hearts of obese diabetic db/db mice at 11 weeks of age. Expression of 12/15-LOX (red) was specifically up-regulated in cardiomyocytes of the hearts. Wheat germ agglutinin (WGA) was used to label cardiomyocytes membranes (green). Upper panel is the staining of cardiomyocytes membranes (green). Middle panel is the staining of 12/15-LOX (red). Lower panel is the merged image of 12/15-LOX, cardiomyocytes membranes and hoechst staining. Scale bar, 60µm. *P<0.05 vs. WT. Error bars indicate s.e.m. n=4-6.

Figure S4  **Plasma levels of free fatty acids and triglycerides are increased in diabetic mice induced STZ treatment.**
Measurement of plasma levels of free fatty acids and triglycerides.
Plasma level of free fatty acids and triglycerides was measured by Free Fatty Ac
id Quantification Kit (BioVision Inc.) and Triglyceride Quantification kit (Wako Chemical Company, Osaka, Japan) according to the manufacturer’s instruction.

(A) Plasma levels of free fatty acids in wild-type (WT), wild-STZ (WT-STZ), Alox15-deficient (KO), Alox15-deficient-STZ (KO-STZ) mice. (B) Plasma levels of triglycerides in WT, KO, WT-STZ and KO-STZ mice. Plasma levels of free fatty acids and triglycerides are significantly increased in WT-STZ mice compared with those in plasma samples from WT mice. This increased level was not affected by the disruption of 12/15-LOX. *P<0.05 vs. WT. Error bars indicate s.e.m. n=4-6.

**Figure S5**  **Cardiac expression of 12/15-LOX is not induced by treatment of palmitic acids**

Expression of 12/15-LOX in cardiomyocytes after treatment of palmitic acids (100uM). Palmitic acid did not affect the expression of 12/15-LOX in cardiomyocyte. Error bars indicate s.e.m. n=4

**Figure S6**  **Cardiac expression of 12/15-LOX is inhibited by insulin treatment in the diabetic hearts.**

Cardiac expression of 12/15-LOX after insulin treatment in diabetic mice by RT-PCR. Treatment with long-acting insulin decreased the cardiac expression of 12/15-LOX induced by hyperglycemia. We performed RT-PCR analysis for 12/15-LOX in the heart was examined at 4 weeks after induction of diabetes. *P<0.05 vs. WT, #P<0.05 vs. WT-STZ. Data are shown as mean+s.e.m. N=4-6.

**Insulin treatment.**

One week after induction of diabetes, the mice were treated with long-acting insulin degludec (Novo Nordisk Pharma Ltd), 0.5–1.5 units s.c. accordingly to plasma glucose levels, once a day for 3 weeks.

**Figure S7**  **Expression of endoplasmic reticulum stress related proteins in the diabetic heart.**

Western blot analysis of Bip and CHOP in the hearts of wild-type (WT), wild-STZ (WT-STZ), Alox15-deficient-STZ (KO-STZ) mice. Cardiac expression of Bip and CHOP level was significantly increased in WT-STZ heart compared to WT heart, and these increases was significantly inhibited by disruption of 12/15-LOX. Data are shown
representative of 1 experiment out of 4.

**Figure S8**  *Cardiac expression of TNF-α and collagen markers are inhibited by treatment with 12/15-LOX inhibitor in the diabetic heart.*

(A, B) RT-PCR analysis for TNF-α, collagen1α2 and collagen3α1 in the hearts of WT, KO, WT-STZ, KO-STZ and WT-STZ+CDC at 4 weeks after induction of diabetes. 12/15-LOX inhibitor (CDC), 8mg/kg once a day, was administered by subcutaneous injection to WT-STZ for 4 weeks. Increased expression of TNF-α, collagen1α2 and collagen3α1 in WT-STZ were significantly inhibited in WT-STZ+CDC as well as KO and KO-STZ. *P<0.05 vs. WT, #P<0.05 vs. WT-STZ+CDC. Error bars indicate s.e.m. n= 4-6 in each group.*